Introduction to the manufacturing company and brand of Serputinib/Serpatinib

The international trade name of Selpercatinib is Retevmo®, and the main company for original research, development and global commercialization is Eli Lilly and Company (Eli Lilly), which is its main promotional brand and source of instructions for European, American and many international markets. Eli Lilly is responsible for overall clinical development, regulatory applications and global supply chain planning in drug R&D and global marketing, and provides complete indications, dosing recommendations and safety information on its official website and drug inserts.

On the commercialization path in the Chinese market, drug licensing, registration and local promotion are often undertaken by partners. After Seputinib was approved to enter China, some public reports and announcements showed that Chinese companies participated in the localized registration or commercialization or acted as cooperative promoters in order to better meet China's regulatory, production and market access requirements. In other words, there is often a division of labor between "who manufactures" and "who promotes" international pharmaceutical companies and local partners: Eli Lilly, as the original researcher, controls global intellectual property and pharmaceutical information, while local companies are responsible for registration, logistics and marketing in China.

Seputinib's product positioning is very clear: it is one of the first small molecule highly selective inhibitors for RET gene-driven solid tumors (including RET fusion-positive non-small cell lung cancer (NSCLC),RET mutation-positive medullary thyroid cancer and radioactive iodine-refractory thyroid cancer). Eli Lilly's official information provides detailed guidance on its dosing regimen, dose grading, and adverse reaction management. Dosage adjustment recommendations for different weights, ages, and tumor types are also listed in the instructions. The clinical team must strictly select targeted patients based on genetic testing results when using it to reduce ineffective medication and unnecessary expenses.

To sum up, Seputinib is an innovation led by Eli Lilly internationally RET inhibitor brand, entering the Chinese market involves local registration and joint promotion with cooperative companies.

Reference:https://en.wikipedia.org/wiki/Selpercatinib